## Francisco Batel Marques

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10693577/publications.pdf

Version: 2024-02-01

1040056 1281871 11 219 9 11 citations h-index g-index papers 11 11 11 360 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Spontaneous reports of hypersensitivity adverse drug reactions in Portugal: a retrospective analysis. Expert Opinion on Drug Safety, 2020, 19, 763-769.	2.4	3
2	A comparison between two recommendations to conduct and report systematic reviews on drug's safety. Systematic Reviews, 2019, 8, 238.	5.3	1
3	Statins and risk of cataracts: A systematic review and metaâ€analysis of observational studies. Cardiovascular Therapeutics, 2018, 36, e12480.	2.5	14
4	A systematic review of observational studies evaluating costs of adverse drug reactions. ClinicoEconomics and Outcomes Research, 2016, Volume 8, 413-426.	1.9	41
5	Testing the usefulness of the number needed to treat to be harmed (NNTH) in benefit-risk evaluations: case study with medicines withdrawn from the European market due to safety reasons. Expert Opinion on Drug Safety, 2016, 15, 1301-1312.	2.4	13
6	Drug-Induced Ocular Adverse Reactions: Review of the Safety Alerts Issued During the Last Decade. Journal of Ocular Pharmacology and Therapeutics, 2015, 31, 258-268.	1.4	12
7	Nurses' spontaneous reporting of adverse drug reactions: expert review of routine reports. Journal of Nursing Management, 2014, 22, 322-330.	3.4	18
8	Drug-safety alerts issued by regulatory authorities: usefulness of meta-analysis in predicting risks earlier. European Journal of Clinical Pharmacology, 2014, 70, 745-756.	1.9	10
9	Sources of information used by regulatory agencies on the generation of drug safety alerts. European Journal of Clinical Pharmacology, 2013, 69, 2083-2094.	1.9	27
10	Multiple drug exposure as a risk factor for the seriousness of adverse drug reactions. Journal of Nursing Management, 2011, 19, 395-399.	3.4	21
11	Causality assessment of adverse drug reactions: comparison of the results obtained from published decisional algorithms and from the evaluations of an expert panel. Pharmacoepidemiology and Drug Safety, 2005, 14, 885-890.	1.9	59